RT-210

RT-210 is a preclinical-stage paracrine gene therapy candidate developed by Renova Therapeutics for the treatment of metabolic conditions, including type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome. The therapy utilizes Renova's proprietary Paracrine Gene Therapy (PGT) platform, which involves the delivery of a transgene to a specific tissue (such as the liver or muscle) to induce the production and systemic secretion of a therapeutic protein. This approach aims to provide sustained levels of the therapeutic agent, potentially improving glucose homeostasis and insulin sensitivity. While Renova's lead metabolic programs often utilize Urocortin 2 (UCN2), RT-210 is listed as a distinct program from the RT-200 (UCN2 gene therapy) program in the company's pipeline, and its specific transgene has not been publicly disclosed.